Drugs Made In America Acquisition II Corp. (DMII)
Market Closed
27 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
10. 11
+0.01
+0.0495%
$
643.37M Market Cap
- P/E Ratio
- Div Yield
80,439 Volume
- Eps
$ 10.1
Previous Close Want to track DMII and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Drugs Made In America Acquisition II Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Daniel L. Lippincott Karpus Management Inc. | 2.6M | $25.9M | $26.21M | $311,751.02 | 1.2% |
| SK Steven Katznelson Radcliffe Capital Management LP | 575,721 | $5.7M | $5.81M | $106,500.69 | 1.87% |
| BO Brian Oliveira Clear Street Group Inc. | 15,345 | $151,915.51 | $154,831.05 | $2,915.54 | 1.92% |
| MCS Mercuria Capital Strategies LLC Mercuria Capital Strategies LLC | 750,000 | $7.48M | $7.56M | $86,250 | 1.15% |
| AAS ABC Arbitrage SA ABC Arbitrage SA | 40,000 | $396,000 | $403,200 | $7,200 | 1.82% |
 Mikhail Shilshtut Limestone Investment Advisors LP | 11,900 | $118,643 | $120,190 | $1,547 | 1.3% |
